DIASORIN

Analysis of Diasorin share price

BUY   SELL
68% of retail investor accounts lose money when trading CFDs with this provider.
 
Chart provided by Tradingview

Before you start trading on Diasorin's share price online, we would like to give you some information about this company and its current situation. We will discover in particular what are the activities of this group, its main competitors or partners but also the strengths and weaknesses of this company.

Elements that can influence the price of this asset:

Analysis N°1

The Diasorin Group's new product launches and the financial impact of bringing these products to market will of course be followed with great attention.

Analysis N°2

We will also keep an eye on the research and development activities of this company with the clinical tests carried out each year and the level of investment in R&D.

Analysis N°3

It will also be necessary to monitor the operations enabling Diasorin to penetrate new markets, particularly through international partnerships.

Analysis N°4

Reimbursement levels from social security schemes will also have an impact on Diasorin's sales and therefore on its profitability.

Analysis N°5

In the same way, we will monitor any change in regulations, particularly in the European market, where Diasorin's presence is important.

Analysis N°6

Finally, we will of course keep a close eye on the competition from new technologies in the field of diagnostics.

68% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on eToro

General presentation of Diasorin

Diasorin is an Italian company specialized in the development, manufacture and sale of in vitro diagnostic reagents. More specifically, the products developed and marketed by Diasorin are most often used in the treatment of infectious and viral diseases, thyroid pathologies, cancers and other such diseases.

 Currently, the Diasorin Group has a network of 7 production sites located mainly in Italy, but also in the United States for two of them, in Germany, the United Kingdom, Ireland and South Africa.

From the point of view of the geographical distribution of the group's activities in terms of turnover, Diasorin generates 22.2% of its turnover in Italy, 27.1% of its turnover in the rest of Europe, 32% of its turnover in North America and 18.7% in the rest of the world.

Analysis of Diasorin share price
68% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on eToro

The major competitors of Diasorin

Of course, Diasorin is not the only company active in the field of medical devices and diagnostic solutions. In fact, this company faces various competitors that we propose to discover here in more detail.

Johnson & Johnson 

The American group Johnson & Johnson is a serious competitor of Diasorin since it offers medical devices through products used in surgery, orthopedics, in the treatment of diabetes or certain cardiovascular diseases. It is one of the world leaders in this sector.

Fresenius 

Fresenius is also a major competitor and is the world's leading supplier of devices for kidney patients. It is active in the provision of clinical services and the manufacture of dialysis machines.

Eurofins 

Eurofins, the world's leading provider of biological services to industry, hospitals and healthcare professionals, is also worth watching.

Thermofisher

The American group Thermofisher is another strong opponent for Diasorin as it specializes in diagnostic and analytical tools, software equipment and other such products.

Biomerieux 

There will also be competition from the French group Biomerieux, which is currently the leader in the in vitro diagnostics sector with products for detecting infectious diseases, cancers and cardiovascular pathologies.


The major partners of Diasorin

Of course, the Diasorin Group has also often relied on the establishment of strategic alliances with other companies to boost the growth of its activities and gain in development. To better understand the value of such partnerships, here is a specific and recent example.

This is a large-scale partnership that was signed in 2018 between Diasorin and Qiagen. The main objective of this partnership is to enable companies to offer new automated TB detection capabilities to their customers. This collaboration will add a diagnostic test called QuantiFERON-TB from Qiagen to Diasorin's Liaison line of automated analyzers. The results of the tests performed by this device can be analyzed by Liaison.

Liaison users will then be able to use the Qiagen reference test to protect at-risk patients by detecting latent TB infection through a fully automated and flexible workflow.

Of course, this is a past example of a major partnership of this company, but you should of course focus your attention on future partnerships that will undoubtedly influence the evolution of this stock price.

68% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on eToro
The factors in favour of a rise in the Diasorin share price:

Let's take a moment to analyze the main strengths and weaknesses of the Diasorin Group and therefore of its stock.

  • Firstly, the Diasorin group benefits from a very advantageous strategic positioning in the field of immunoassays with no less than 120 tests currently developed and included in its portfolio.
  • Another major advantage of this company is its ability to develop in the molecular biology sector. This segment has been booming for several years now and should therefore enable Diasorin to stay one step ahead of its competitors and generate new revenues.
  • Diasorin's takeovers of other companies are also a strong point to remember as they allow it to develop its activities and gain growth and presence on the market. This was the case recently with the acquisition of Focus Diagnostic.
  • We can also underline the good development and international expansion strategy of this company, especially in specific and particularly dynamic geographical areas such as Europe-Africa, Asia-Pacific including China. This presence in the emerging markets and the most active markets guarantees Diasorin to generate sufficiently interesting revenues in the medium and long term.
The factors in favour of a drop in the Diasorin share price:

Of course and if the Diasorin group has many strengths that could allow it to improve its growth in the future, it also has some weaknesses that you should also be aware of and that can indeed negatively influence the price of this stock. So here are the main weaknesses of this company:

  • First of all, we note that the activities of this company depend to a very large extent on the CLIA technology, which could pose some problems of profitability in the event of the development of a new, more advanced technology that would replace it.
  • Finally, due to the international dimension of Diasorin's activities, the company is relatively exposed to problems related to health regulations or to the reimbursement of certain treatments by health insurance companies.
The information supplied here is only for indicative purposes and should not be used without the completion of a comprehensive and complete fundamental analysis of this asset notably taking into account exterior data, future publications and announcements and all fundamental events and news that could influence the strengths and weaknesses or make them more or less significant. This information does not in any way constitute recommendations relating to the completion of transactions.

Frequently Asked Questions

When was the Diasorin group created and what is its origin?

Diasorin's history began in 1968 when Fiat and Montecatini decided to create Sorin Biomedica with Societa Ricerche Impianti Nucleari-Sorin. Later, this new company would increase its growth by taking control of American Incstar in 1997 and later selling part of its operations to American Standard. The Diasorin company as we know it today was created in 2000 through a management buyout led by Carlo Rosa and Gustavo Denegri.

In which countries does the Diasorin Group operate?

The Diasorin group carries out a large part of its activities in Europe and Africa with 46.1% of its turnover realized on these two continents. But it also realizes almost 29.1% of its turnover in North America, more precisely in the United States and Canada, 19% in Asia and Oceania and finally 6.3% in Latin America. Its main production sites are located in Italy, in Saluggia and Gerenzano, in Germany in Dietzenbach, in the United States in Stillwater and Cypress and in the United Kingdom in Dartford.

Where is the Diasorin share quoted today?

It is of course on the Italian stock market that the Diasorin share price is quoted today. This quotation is done on the Bolsa Italiana, and more precisely on the Mercato Telematico Azionario. It is a live and continuous quotation which is done during 5 days a week during the opening hours of this stock exchange.

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.